Insilico Medicine says its drug Rentosertib—the first medicine fully discovered and designed using artificial intelligence—could enter Phase 3 clinical trials within the next 18 months, marking the final stage before regulatory approval.
The drug targets idiopathic pulmonary fibrosis, a deadly lung disease that kills around 40,000 people in the US each year. In a Phase 2 trial involving 71 patients in China, Rentosertib improved lung function with few side effects.
Read More
